Norges Bank Kal Vista Pharmaceuticals, Inc. Transaction History

Norges Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.35 - $12.49 $1.36 Million - $1.64 Million	131,300 New	131,300 $1.55 Million
Q3 2023 Nov 13, 2023	SELL	$8.95 - $11.35 $133,355 - $169,115	-14,900 Closed	0 $0
Q2 2023 Aug 14, 2023	SELL	$7.73 - $10.57 $115,177 - $157,493	-14,900 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $919,380 - $3.12 Million	218,900 New	218,900 $1.48 Million
Q3 2022 Nov 13, 2023	BUY	$9.85 - $16.83 $146,765 - $250,766	14,900 New	14,900 $216,000
Q2 2022 Aug 14, 2023	BUY	$8.16 - $15.1 $121,584 - $224,990	14,900 New	14,900 $146,000
Q4 2020 Feb 10, 2021	SELL	$12.88 - $19.47 $275,632 - $416,658	-21,400 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$9.83 - $13.99 $210,362 - $299,386	21,400 New	21,400 $269,000
Q3 2020 Nov 10, 2020	SELL	$9.83 - $13.99 $918,122 - $1.31 Million	-93,400 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$6.75 - $12.89 $630,450 - $1.2 Million	93,400 New	93,400 $1.13 Million

126

47.9M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $214M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.